Catestatin serum levels are increased in male patients with obstructive sleep apnea

Borovac, Josip Anđelo; Đogaš, Zoran; Šupe‐Domić, Daniela; Galić, Tea; Božić, Joško

doi:10.1007/s11325-018-1703-x

Cited by 16 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been previously shown that inflammatory process affects the secretion of enterochromaffine cells in the gut of IBD patients [20]. Accordingly, it seems that ChgA, a precursor of CST, is increased in colon and plasma in patients with IBD [31,44,45].…”

Section: Discussionmentioning

confidence: 94%

“…Catestatin (CST) is a novel multifunctional peptide proteolytically cleaved from chromogranin A (ChgA), that primarily acts as an inhibitor of catecholamine secretion in vitro in cultured cells and in vivo from mouse adrenal medulla, and as stimulator of histamine release [10][11][12]. Studies implicate its connection with multiple functions throughout various systems, including vasodilatation [13], immunoregulation [14], insulin resistance [15][16][17], antimicrobial effect [18,19] and obstructive sleep apnea [20]. Furthermore, it has been reported to be a key regulator of cardiovascular function, with cardioprotective effects including exhibiting the trough suppression of atherosclerosis [21], negative inotropic and lusitropic cardiac effects [22], inhibition of coronary vasoconstriction [21], a reduction in oxidative stress in ischemic-reperfused myocardium [22], a decrease in endothelial inflammation and regulation of blood pressure [10,[23][24][25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Živković

Matetić

Hadjina

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Catestatin (CST) is an important peptide in the pathophysiology of chronic inflammatory disorders. However, clinical studies on inflammatory bowel disease (IBD) patients are lacking. Our goal was to investigate CST concentrations in IBD patients compared to healthy subjects. Additionally, we aimed to determine arterial stiffness parameters in relation to CST. This cross-sectional study compared 80 IBD patients (45 Crohn’s disease (CD) and 35 ulcerative colitis (UC) patients) with 75 control subjects. Serum CST levels were significantly higher in the IBD group compared to control subjects (11.29 ± 9.14 vs. 7.13 ± 6.08 ng/mL, p = 0.001) and in the UC group compared to CD patients (13.50 ± 9.58 vs. 9.03 ± 6.92 ng/mL, p = 0.021), irrespective of age and BMI. IBD patients exhibited significantly higher values of heart rate adjusted central augmentation index (cAIx-75) (14.88 ± 10.59 vs. 6.87 ± 9.50 %, p < 0.001) and pulse wave velocity (PWV) (8.06 ± 3.23 vs. 6.42 ± 1.47 m/s, p < 0.001) compared to control group. Furthermore, PWV was the only significant independent correlate of CST (B = 1.20, t = 4.15, p < 0.001), while CST, PWV, cAIx-75, high-sensitivity C-reactive protein and BMI were significant predictors of positive IBD status (1.089 (1.022–1.161), 1.515 (1.166–1.968), 1.060 (1.024–1.097), 1.458 (1.116–1.906), 0.793 (0.683–0.920), respectively). Serum CST levels were significantly higher in IBD patients compared to controls and an independent positive correlation of CST with PWV existed. Therefore, it is possible that CST could have a role in the complex pathophysiology of IBD and its cardiovascular complications.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Živković

Matetić

Hadjina

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…In terms of catestatin and lipid metabolism, no comparable data are available for the HF population. In a study among untreated hypertensive patients, catestatin levels correlated positively with HDL-cholesterol levels but no associations were observed with respect to the total cholesterol or other cholesterol fractions [50], while CST correlated negatively with HDL cholesterol among obstructive sleep apnea patients [11]. Similarly, catestatin significantly retarded aortic atherosclerotic lesions with declined lipoprotein-induced foam cell formation in a preclinical experiment [51], while its levels were inversely associated with the severity of atherosclerosis, among patients with CAD [52].…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, catestatin (CST) is a pleiotropic cardioprotective peptide that counterbalances the negative effects of SNS by promoting vasodilation [8] and by inhibiting catecholamine secretion [9,10]. Previous studies have demonstrated that high levels of CST might reflect increased sympathoadrenal activity [11,12,13], are associated with increased mortality in HF [14,15], and are a marker of poor ventricular remodeling after myocardial infarction (MI) [16]. Furthermore, CST levels were associated with disease severity in HF [17,18] and were similar between patients with preserved (HFpEF) and reduced (HFrEF) left ventricular ejection fraction (LVEF) phenotypes [17].…”

Section: Introductionmentioning

confidence: 99%

Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study

Borovac

Glavaš

Grabovac

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

The role of catestatin (CST) in acutely decompensated heart failure (ADHF) and myocardial infarction (MI) is poorly elucidated. Due to the implicated role of CST in the regulation of neurohumoral activity, the goals of the study were to determine CST serum levels among ninety consecutively enrolled ADHF patients, with respect to the MI history and left ventricular ejection fraction (LVEF) and to examine its association with clinical, echocardiographic, and laboratory parameters. CST levels were higher among ADHF patients with MI history, compared to those without (8.94 ± 6.39 vs. 4.90 ± 2.74 ng/mL, p = 0.001). CST serum levels did not differ among patients with reduced, midrange, and preserved LVEF (7.74 ± 5.64 vs. 5.75 ± 4.19 vs. 5.35 ± 2.77 ng/mL, p = 0.143, respectively). In the multivariable linear regression analysis, CST independently correlated with the NYHA class (β = 0.491, p < 0.001), waist-to-hip ratio (WHR) (β = −0.237, p = 0.026), HbA1c (β = −0.235, p = 0.027), LDL (β = −0.231, p = 0.029), non-HDL cholesterol (β = −0.237, p = 0.026), hs-cTnI (β = −0.221, p = 0.030), and the admission and resting heart rate (β = −0.201, p = 0.036 and β = −0.242, p = 0.030), and was in positive association with most echocardiographic parameters. In conclusion, CST levels were increased in ADHF patients with MI and were overall associated with a favorable cardiometabolic profile but at the same time reflected advanced symptomatic burden (CATSTAT-HF ClinicalTrials.gov number, NCT03389386).

show abstract

“…Previous studies in an adult population of hypertensive patients who were mostly obese with MS and patients with OSA who were mostly overweight or obese identified significant correlations between catestatin and HDL cholesterol levels, but interestingly reported opposing results . In addition, according to Durakoğlugil et al, triglyceride levels negatively correlate with plasma catestatin concentrations.…”

Section: Discussionmentioning

confidence: 93%

Serum catestatin concentrations are decreased in obese children and adolescents

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: Catestatin is a chromogranin A-derived peptide with a wide spectrum of biological activities, such as inhibiting catecholamine release, decreasing blood pressure, stimulating histamine release, reducing beta-adrenergic stimulation, and regulating oxidative stress.Objectives: The aims of our study were to determine serum catestatin concentrations in obese children and adolescents in regard to presence or absence of metabolic syndrome (MS) and to evaluate the possible relations between catestatin levels and other cardiovascular risk factors.Subjects: Ninety-two obese subjects with a body mass index z score > 2, aged 10 to 18 years, and 39 healthy, normal weight controls were enrolled in the study.Methods: Serum catestatin concentrations were measured using an enzyme-linked immunosorbent assay.Results: Significantly lower serum catestatin concentrations were recorded in the group of obese subjects compared with a control group (10.03 ± 5.05 vs 13.13 ± 6.25 ng/mL, P = 0.004). Further analyses revealed significantly lower catestatin concentrations in the subgroup of obese patients with MS (9.02 ± 4.3 vs 10.54 ± 5.36 vs 13.13 ± 6.25, P = 0.008).Serum catestatin concentrations were significantly negatively correlated with diastolic blood pressure (r = −0.253, P = 0.014), homeostatic model assessment of insulin resistance (r = −0.215, P = 0.037) and high sensitivity C-reactive protein (r = −0.208, P = 0.044). Conclusions:To the best of our knowledge, this study is the first to report catestatin concentrations in obese children and adolescents and their possible relations with MS and cardiovascular risk factors in a pediatric population. Obese subjects with MS have lower serum catestatin concentrations than obese subjects without MS and controls. K E Y W O R D Sadolescents, catestatin, children, metabolic syndrome, obesity

show abstract

Catestatin serum levels are increased in male patients with obstructive sleep apnea

Cited by 16 publications

References 40 publications

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study

Serum catestatin concentrations are decreased in obese children and adolescents

Contact Info

Product

Resources

About